Amarin Corp

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

News

Movers

AMRN

Amarin Corporation (NASDAQ: AMRN) shares are trading higher Tuesday after the company announced a long-term exclusive license and supply agreement with Recordati S.p.A. to commercialize its cardiovascular drug VAZKEPA (icosapent ethyl) across 59 countries in Europe.

Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA

Business,Handshake,For,Teamwork,Of,Business,Merger,And,Acquisition,successful,Negotiate,hand

Biotech

Health Care

General

Amarin signs $175 million Vazkepa deal with Recordati, plans global restructuring and targets $70 million in cost cuts to improve cash flow

Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges

Woman,Hand,Holding,Plus,Icon,For,The,Healthcare,Medical,Icon.

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

LXRX

Top 2 Health Care Stocks That May Crash This Month

Amarin Corporation plc - American Depositary Shares

Amarin Corp PLC

Press Releases

Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist

Management

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Earnings

Amarin Reports First Quarter 2025 Financial Results

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

Abeona Therapeutics

Absci

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Crescent Biopharma

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Heron Therapeutics

Humacyte

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prime Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Solid Biosciences

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Vigil Neuroscience

XOMA Royalty

Goldman Sachs

Jefferies

Northland Capital Markets

SVB Leerink

Comments

Amarin Corp

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell